Lumacaftor/ivacaftor therapy is associated with reduced hepatic steatosis in cystic fibrosis patients.

World J Hepatol · 2019 · PMC6960296 · PMID 31966908

Europe PMC DOI

hedged sentences

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

did not reach statistical significanceP = 0.06so close (0.05 < p ≤ 0.1)

Though patients with CFRD had lower PDFF (2.2%, 0.0%-14.5%) than patients with NGT (4.9%, 2.4-21.0%) this did not reach statistical significance, P = 0.06.

also in 111,027 other papers

showed a trendno p-value reported

Subjects with hepatic steatosis showed a trend toward younger age that did not reach statistical significance.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.